166 related articles for article (PubMed ID: 15888151)
1. High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Stoebner PE; Lavabre-Bertrand T; Henry L; Guiraud I; Carillo S; Dandurand M; Joujoux JM; Bureau JP; Meunier L
Br J Dermatol; 2005 May; 152(5):948-53. PubMed ID: 15888151
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma.
Henry L; Lavabre-Bertrand T; Douche T; Uttenweiler-Joseph S; Fabbro-Peray P; Monsarrat B; Martinez J; Meunier L; Stoebner PE
Exp Dermatol; 2010 Dec; 19(12):1054-9. PubMed ID: 20707810
[TBL] [Abstract][Full Text] [Related]
3. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous measurement of circulating intercellular adhesion molecule-1 and serum copper zinc superoxide dismutase activity in patients with malignant melanoma.
Wollina U; Karte K; Olbertz K; Hipler UC
Oncol Rep; 1998; 5(2):473-6. PubMed ID: 9468582
[TBL] [Abstract][Full Text] [Related]
5. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Henry L; Lavabre-Bertrand T; Vercambre L; Ramos J; Carillo S; Guiraud I; Pouderoux P; Bismuth M; Valats JC; Demattei C; Duny Y; Chaze I; Funakoshi N; Bureau JP; Daurès JP; Blanc P
Gut; 2009 Jun; 58(6):833-8. PubMed ID: 19201777
[TBL] [Abstract][Full Text] [Related]
6. Circulating vascular endothelial growth factor in cutaneous malignant melanoma.
Pelletier F; Bermont L; Puzenat E; Blanc D; Cairey-Remonnay S; Mougin C; Laurent R; Humbert P; Aubin F
Br J Dermatol; 2005 Apr; 152(4):685-9. PubMed ID: 15840099
[TBL] [Abstract][Full Text] [Related]
7. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin.
Henry L; Le Gallic L; Garcin G; Coux O; Jumez N; Roger P; Lavabre-Bertrand T; Martinez J; Meunier L; Stoebner PE
Br J Dermatol; 2011 Aug; 165(2):311-20. PubMed ID: 21740404
[TBL] [Abstract][Full Text] [Related]
9. [The proteasome and malignant hemopathies].
Lavabre-Bertrand T; Henry L; Guiraud I; Carillo S; Bureau JP
Morphologie; 2000 Jun; 84(265):39-43. PubMed ID: 11048297
[TBL] [Abstract][Full Text] [Related]
10. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
Ivanović V; Demajo M; Krtolica K; Krajnović M; Konstantinović M; Baltić V; Prtenjak G; Stojiljković B; Breberina M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Dimitrijević B
Clin Chim Acta; 2006 Sep; 371(1-2):191-3. PubMed ID: 16650397
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.
Yoshino Y; Kageshita T; Nakajima M; Funakubo M; Ihn H
J Dermatol; 2008 Apr; 35(4):206-14. PubMed ID: 18419677
[TBL] [Abstract][Full Text] [Related]
12. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
13. Quantification of cathepsin D in plasma of patients with malignant melanoma.
Westhoff U; Fox C; Otto FJ
Anticancer Res; 1998; 18(5B):3785-8. PubMed ID: 9854496
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
15. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
16. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
Ma W; Kantarjian H; O'Brien S; Jilani I; Zhang X; Estrov Z; Ferrajoli A; Keating M; Giles F; Albitar M
Cancer; 2008 Mar; 112(6):1306-12. PubMed ID: 18224667
[TBL] [Abstract][Full Text] [Related]
18. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
Mouawad R; Spano JP; Comperat E; Capron F; Khayat D
Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
20. Circulating 20S proteasome in patients with non-metastasized breast cancer.
Hoffmann O; Heubner M; Anlasik T; Winterhalter M; Dahlmann B; Kasimir-Bauer S; Kimmig R; Wohlschlaeger J; Sixt SU
Anticancer Res; 2011 Jun; 31(6):2197-201. PubMed ID: 21737641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]